Rahul Vohra sold his email startup Superhuman to Grammarly for $825 million, a second exit that stands in deliberate contrast to his first: the 2012 sale of Rapportive to LinkedIn for a reported $15 million, which preceded a stress-induced hospitalization that forced him to rewrite his operating manual for building companies.
The first exit came with a health cost
Rapportive, a browser plug-in that layered social profiles onto Gmail, moved from first line of code to Y Combinator's summer 2010 cohort in a matter of months. The five-person team was running out of cash when LinkedIn acquired it in February 2012. Vohra, then 27, collapsed outside a San Francisco McDonald's during the sale process; a nurse told him his gastrointestinal reflux disease had aged his insides by ten to twenty years. He spent a week in hospital and a month recovering with family in England before returning to work.
Meditation replaced the grind
The recovery period introduced Vohra to transcendental meditation in the Raj tradition, taught one-on-one by Laurent Valosek of the Peak Leadership Institute. Sessions began as hours-long daily sittings and continue every two to three months. Vohra credits the practice with letting him build Superhuman without repeating the physical collapse that marked his first exit.
The second deal stays quiet on terms
Grammarly's acquisition of Superhuman was announced at an $825 million valuation, but the source discloses no consideration mix, no premium to an undisturbed price, and no break-fee or condition structure. The Rapportive deal similarly lacked public term details beyond the headline figure. In both cases the buyer's rationale is stated as strategic fit rather than quantified synergy.
The founder's view on the market
"I personally find it sad and dismaying when founders in their 20s… are running themselves into the ground, often much worse than what I did," Vohra told Fortune. "They're doing what I did plus stupid hours, and they're wearing that as a badge of honor."
What the structure signals
Two exits, two opaque term sheets, and a founder who treats his own physiology as a leading indicator. The market still rewards the exit headline; the terms that reveal leverage, cash versus stock, earnouts, indemnity caps, remain private. Vohra's second outcome suggests a founder who learned to negotiate with his own biology first.